首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2662411篇
  免费   194242篇
  国内免费   6249篇
耳鼻咽喉   36863篇
儿科学   88395篇
妇产科学   74955篇
基础医学   380036篇
口腔科学   77156篇
临床医学   234228篇
内科学   514678篇
皮肤病学   59332篇
神经病学   206793篇
特种医学   102355篇
外国民族医学   610篇
外科学   408094篇
综合类   62974篇
一般理论   790篇
预防医学   197209篇
眼科学   63464篇
药学   199005篇
  17篇
中国医学   6987篇
肿瘤学   148961篇
  2018年   28562篇
  2017年   21943篇
  2016年   24190篇
  2015年   27853篇
  2014年   38896篇
  2013年   57016篇
  2012年   79011篇
  2011年   83812篇
  2010年   49534篇
  2009年   46373篇
  2008年   78465篇
  2007年   83990篇
  2006年   84849篇
  2005年   82096篇
  2004年   78899篇
  2003年   75372篇
  2002年   73201篇
  2001年   130092篇
  2000年   133352篇
  1999年   111194篇
  1998年   29194篇
  1997年   25476篇
  1996年   25576篇
  1995年   25778篇
  1994年   24078篇
  1993年   22083篇
  1992年   86884篇
  1991年   84576篇
  1990年   82072篇
  1989年   79376篇
  1988年   73039篇
  1987年   71496篇
  1986年   67781篇
  1985年   64584篇
  1984年   47637篇
  1983年   40919篇
  1982年   23576篇
  1981年   21037篇
  1979年   43612篇
  1978年   30243篇
  1977年   25960篇
  1976年   24220篇
  1975年   26142篇
  1974年   31464篇
  1973年   30247篇
  1972年   28508篇
  1971年   26373篇
  1970年   24610篇
  1969年   23395篇
  1968年   21963篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ObjectiveTo determine prognostic factors and survival patterns for different treatment modalities for nasal cavity (NC) and paranasal sinus (PS) mucosal melanoma (MM).MethodsPatients from 1973 to 2013 were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier method and multivariable cox proportional hazard modeling were used for survival analyses.ResultsOf 928 cases of mucosal melanoma (NC = 632, PS = 302), increasing age (Hazard Ratio [HR]:1.05/year, p < 0.001), T4 tumors (HR: 1.81, p = 0.02), N1 status (HR: 6.61, p < 0.001), and PS disease (HR: 1.50, p < 0.001) were associated with worse survival. Median survival length was lower for PS versus NC (16 versus 26 months, p < 0.001). Surgery and surgery + radiation therapy (RT) improved survival over non-treatment or RT alone (p < 0.001). Adding RT to surgery did not yield a survival difference compared with surgery alone (p = 0.43). Five-year survival rates for surgery and surgery + RT were similar, at 27.7% and 25.1% (p = 0.43).ConclusionSurgery increased survival significantly over RT alone. RT following surgical resection did not improve survival.  相似文献   
2.
3.
4.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
5.
Pituitary - Our aim was to investigate the changes in the composition of oral and gut microbiota in patients with newly diagnosed acromegaly and their relationship with IGF-1 levels. Oral and fecal...  相似文献   
6.
7.
Pharmaceutical Research - The quality testing and approval procedure for most pharmaceutical products is a streamlined process with standardized procedures for the determination of critical quality...  相似文献   
8.
Graefe's Archive for Clinical and Experimental Ophthalmology - To investigate comorbidities and medications associated with acute (ASCH) and delayed (DSCH) suprachoroidal hemorrhage (SCH), and...  相似文献   
9.
Pharmaceutical Research - Cancer is associated with a comprehensive burden that significantly affects patient’s quality of life. Even though patients’ disease condition is improving...  相似文献   
10.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号